Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: semi_infinite who wrote (249)	2/2/2019 5:37:04 PM
From: scaram(o)uche	Respond to of 294

Cool paper! Thanks. And what do we get from R&D at Trillium? Isotype swap. >> Any comments on pros and cons of bspec vs combo approaches? << I'd characterize this evidence in favor of bispecific as weak. Pet peeve.... groups of five WT mice. Why not 20? Figures 4b and 4d are perhaps rigged for visual pleasure, extending to only ten days beyond the point where all combo mice have died. Grain of salt, data points in favor of the bispecific.